PT1052246E - Derivados de amino-acidos contendo fluor - Google Patents
Derivados de amino-acidos contendo fluorInfo
- Publication number
- PT1052246E PT1052246E PT99901877T PT99901877T PT1052246E PT 1052246 E PT1052246 E PT 1052246E PT 99901877 T PT99901877 T PT 99901877T PT 99901877 T PT99901877 T PT 99901877T PT 1052246 E PT1052246 E PT 1052246E
- Authority
- PT
- Portugal
- Prior art keywords
- disturbance
- amino acid
- acid derivatives
- fluorine
- disease
- Prior art date
Links
- 150000003862 amino acid derivatives Chemical class 0.000 title abstract 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 229910052731 fluorine Inorganic materials 0.000 abstract 2
- 239000011737 fluorine Substances 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 abstract 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 239000003823 glutamate receptor agonist Substances 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 230000004899 motility Effects 0.000 abstract 1
- 230000003387 muscular Effects 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 210000000278 spinal cord Anatomy 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1544498 | 1998-01-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1052246E true PT1052246E (pt) | 2003-06-30 |
Family
ID=11888991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT99901877T PT1052246E (pt) | 1998-01-28 | 1999-01-27 | Derivados de amino-acidos contendo fluor |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6316498B1 (pt) |
| EP (1) | EP1052246B1 (pt) |
| KR (1) | KR100446892B1 (pt) |
| CN (1) | CN1182105C (pt) |
| AT (1) | ATE236118T1 (pt) |
| AU (1) | AU734812B2 (pt) |
| CA (1) | CA2318800C (pt) |
| DE (1) | DE69906492T2 (pt) |
| DK (1) | DK1052246T3 (pt) |
| ES (1) | ES2191412T3 (pt) |
| HK (1) | HK1036792A1 (pt) |
| PT (1) | PT1052246E (pt) |
| WO (1) | WO1999038839A1 (pt) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1110943B1 (en) | 1998-08-31 | 2004-06-16 | Taisho Pharmaceutical Co. Ltd. | 6-fluorobicyclo 3. 1.0]hexane derivatives |
| JP4399932B2 (ja) | 1998-12-18 | 2010-01-20 | 大正製薬株式会社 | 中間体及びそれを用いた含フッ素アミノ酸化合物の製造方法 |
| AU2002237717A1 (en) * | 2000-10-30 | 2002-05-27 | Annovis, Inc. | Method for modulation, stimulation, and inhibition of glutamate reuptake |
| WO2002055485A1 (en) | 2001-01-11 | 2002-07-18 | Eli Lilly And Company | Prodrugs of excitatory amino acids |
| CN1267407C (zh) | 2001-01-11 | 2006-08-02 | 伊莱利利公司 | 兴奋性氨基酸前体药物 |
| EP1310480A1 (en) * | 2001-11-07 | 2003-05-14 | Eli Lilly & Company | Prodrugs of excitatory amino acids |
| JP4124656B2 (ja) * | 2001-03-14 | 2008-07-23 | 大正製薬株式会社 | ビシクロカルボン酸誘導体の製造方法 |
| US7456221B2 (en) | 2001-12-21 | 2008-11-25 | Eli Lilly And Company | Prodrugs of excitatory amino acids |
| AU2003232146B2 (en) | 2002-06-11 | 2009-06-18 | Eli Lilly And Company | Prodrugs of excitatory amino acids |
| EP2184062A1 (en) * | 2005-06-22 | 2010-05-12 | Ajinomoto Co., Inc. | Use of glutamic acid and a nucleic acid as metabotropic glutamate receptor activators |
| TWI417095B (zh) * | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途 |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| TW200845978A (en) * | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| TW200927731A (en) * | 2007-09-14 | 2009-07-01 | Ortho Mcneil Janssen Pharm | 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones |
| WO2009033702A1 (en) | 2007-09-14 | 2009-03-19 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones |
| PT2203439E (pt) | 2007-09-14 | 2011-02-11 | Ortho Mcneil Janssen Pharm | 4-fenil-3,4,5,6-tetra-hidro-2h,1'h-[1,4']bipiridinil-2'- onas 1',3'-dissubstituídas |
| EP2220083B1 (en) * | 2007-11-14 | 2017-07-19 | Janssen Pharmaceuticals, Inc. | Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| EP2344470B1 (en) | 2008-09-02 | 2013-11-06 | Janssen Pharmaceuticals, Inc. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
| AU2009304293B2 (en) | 2008-10-16 | 2012-04-26 | Addex Pharma S.A. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
| CN102232074B (zh) | 2008-11-28 | 2014-12-03 | 奥梅-杨森制药有限公司 | 作为代谢性谷氨酸盐受体调节剂的吲哚和苯并噁嗪衍生物 |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| ES2409006T3 (es) | 2009-05-12 | 2013-06-24 | Janssen Pharmaceuticals Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de los receptores mGluR2 |
| CA2760741C (en) | 2009-05-12 | 2018-05-01 | Addex Pharma S.A. | 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders |
| CA2815002C (en) | 2010-11-08 | 2019-10-22 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| JP5852665B2 (ja) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
| CN103298810B (zh) | 2010-11-08 | 2016-03-16 | 杨森制药公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
| HUE030171T2 (en) | 2011-06-17 | 2017-05-29 | Lilly Co Eli | Bicyclo (3.1.0) hexane-2,6-dicarboxylic acid derivatives such as mGlu2 receptor agonists |
| LT2857385T (lt) | 2012-06-01 | 2017-10-25 | Taisho Pharmaceutical Co., Ltd. | Fluoro turinčios aminorūgšties provaistas |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| KR20200036063A (ko) | 2014-01-21 | 2020-04-06 | 얀센 파마슈티카 엔.브이. | 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도 |
| JP6629740B2 (ja) | 2014-01-21 | 2020-01-15 | ヤンセン ファーマシューティカ エヌ．ベー． | 代謝型グルタミン酸作動性受容体サブタイプ２の正のアロステリック調節因子またはオルトステリックアゴニストを含む組み合わせ、およびそれらの使用 |
| CN105017048A (zh) * | 2015-07-01 | 2015-11-04 | 上海应用技术学院 | 一种含有四取代碳手性中心的α-氟烷基-α-氨基酸类化合物及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL182285B1 (pl) | 1994-08-12 | 2001-12-31 | Lilly Co Eli | Syntetyczne aminokwasy oraz ich estry i srodki farmaceutyczne je zawierajace PL PL PL PL PL PL PL |
| US5750566A (en) | 1994-08-12 | 1998-05-12 | Eli Lilly And Company | Synthetic excitatory amino acids |
| IL118727A (en) * | 1995-06-29 | 2003-01-12 | Lilly Co Eli | (-)-2-spiro-5-hydantoinbicyclo [3.1.0] hexane-6-carboxylic acid, salts thereof and use thereof for the preparation of (+)-(2) aminobicyclo [3.1.0] hexane-2,6-dicarboxylic acid |
| ZA983930B (en) | 1997-05-14 | 1999-11-08 | Lilly Co Eli | Excitatory amino acid receptor modulators. |
-
1999
- 1999-01-27 AU AU21835/99A patent/AU734812B2/en not_active Ceased
- 1999-01-27 WO PCT/JP1999/000324 patent/WO1999038839A1/ja active IP Right Grant
- 1999-01-27 AT AT99901877T patent/ATE236118T1/de active
- 1999-01-27 CN CNB99804606XA patent/CN1182105C/zh not_active Expired - Fee Related
- 1999-01-27 CA CA002318800A patent/CA2318800C/en not_active Expired - Fee Related
- 1999-01-27 KR KR10-2000-7008189A patent/KR100446892B1/ko not_active IP Right Cessation
- 1999-01-27 PT PT99901877T patent/PT1052246E/pt unknown
- 1999-01-27 DK DK99901877T patent/DK1052246T3/da active
- 1999-01-27 ES ES99901877T patent/ES2191412T3/es not_active Expired - Lifetime
- 1999-01-27 US US09/601,131 patent/US6316498B1/en not_active Expired - Lifetime
- 1999-01-27 EP EP99901877A patent/EP1052246B1/en not_active Expired - Lifetime
- 1999-01-27 DE DE69906492T patent/DE69906492T2/de not_active Expired - Lifetime
-
2001
- 2001-11-06 HK HK01107767A patent/HK1036792A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US6316498B1 (en) | 2001-11-13 |
| CN1182105C (zh) | 2004-12-29 |
| CN1295557A (zh) | 2001-05-16 |
| EP1052246A1 (en) | 2000-11-15 |
| AU2183599A (en) | 1999-08-16 |
| EP1052246A4 (en) | 2001-11-07 |
| CA2318800A1 (en) | 1999-08-25 |
| HK1036792A1 (en) | 2002-01-18 |
| KR20010034418A (ko) | 2001-04-25 |
| DE69906492D1 (de) | 2003-05-08 |
| KR100446892B1 (ko) | 2004-09-04 |
| DE69906492T2 (de) | 2003-12-18 |
| CA2318800C (en) | 2005-12-20 |
| WO1999038839A1 (fr) | 1999-08-05 |
| EP1052246B1 (en) | 2003-04-02 |
| ATE236118T1 (de) | 2003-04-15 |
| AU734812B2 (en) | 2001-06-21 |
| DK1052246T3 (da) | 2003-06-16 |
| ES2191412T3 (es) | 2003-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1052246E (pt) | Derivados de amino-acidos contendo fluor | |
| HK1049996A1 (en) | 6-FluorobicycloÄ3.1.0Ühexane derivatives | |
| GR3021874T3 (en) | Improvements in or relating to excitatory amino acid receptor antagonists | |
| CY1107401T1 (el) | Παραγωγα βενζοθειαζολιου πα την θεραπευτικη αντιμετωπιση της νοσου alzheimer και της νοσου parkinson | |
| FI941378A (fi) | Bentsimidatsoliyhdisteitä, niiden käyttö ja valmistus | |
| MXPA04005444A (es) | Ureas de 2-aminobenzotiazoles como moduladores de adenosina. | |
| BR9802482A (pt) | Derivados de 5h-tiazolo[3,2-a]pirimidina. | |
| HUP0101220A2 (hu) | NMDA-receptor antagonista 1-(3-heteroaril-propil- vagy -prop-2-enil)-4-benzil-piperidinek, a vegyületeket tartalmazó gyógyszerkészítmények és eljárás az előállításukra | |
| NO903389L (no) | Fremgangsmaate for fremstilling av 1,3-dihydro-1-(pyridinylamino)-2h-indol-2-oner, samt anvendelse som medikamenter. | |
| BR9801157A (pt) | Derivados de adamantano substituìdos por flúor. | |
| EP1016664A4 (en) | CONDENSED THIOPHENE COMPOUNDS AND THEIR USE IN MEDICINE | |
| HU912901D0 (en) | Method for producing 3-(1h-indazole-3-yl)-4-pyridine amines and pharmaceutical preparatives containing said compounds | |
| DK1082116T3 (da) | Anvendelse af 4-piperidinmethanolderivater til behandling af neurologiske sygdomme | |
| JP2004524292A5 (pt) | ||
| PT94205A (pt) | Processo para a preparacao de 4,5,6,11-tetra-hidrobenzo{6,7}ciclo-octa-{1,2-b}tiofen-6,11-iminas e 6,11-di-hidrobenzo{6,7}ciclo-octa-{1,2-b}tiofen-6,11-iminas | |
| ECSP003717A (es) | Derivados de benzodiazepin | |
| ECSP003715A (es) | Derivados de benzodiazepin |